Type 2 Diabetes Prevalent Among People Living With HIV
Approximately 1 in 5 people with HIV also has prevalent DM, and control of hemoglobin A1c levels in these patients may have a beneficial effect on CD4 counts.
Approximately 1 in 5 people with HIV also has prevalent DM, and control of hemoglobin A1c levels in these patients may have a beneficial effect on CD4 counts.
Researchers conducted a Phase 3 trial of patients with community acquired bacterial pneumonia and diabetes to compare delafloxacin treatment with moxiflocacin.
In women with HIV and diabetes mellitus, CD4+ lymphocytes may contribute to the development of diabetes mellitus.
Initiation of therapy with SGLT-2 inhibitors for T2D mellitus is not associated with an increased risk for UTI events compared with initiation of other second-line antidiabetic medications.
Multidrug-resistant gram-negative bacilli were the pathogens commonly found in patients with acute cerebral infarction complicated by diabetes mellitus and nosocomial pulmonary infection.
An association has been identified between newly diagnosed active tuberculosis, diabetes, and body mass index.
Patients with diabetes are at higher risk for hospitalization and mortality because of pneumococcal infection; however, uptake of vaccination remains suboptimal.
People living with HIV, non-alcoholic fatty liver disease, and antiretroviral-associated lipodystrophy may be at an increased risk of developing type 2 diabetes.
Insulin resistance has been identified as a key driver of CVD and other complications in people living with HIV.
In a large cohort of patients with HCV, the use of DAA was associated with significantly lower incidence and risk for subsequent diabetes.